[Our experience with renal adenocarcinoma (III): results of surgical treatment, other treatments. Survival analysis].
Evaluation of survival and results of treatment of renal cell carcinoma. We reviewed the records of 229 consecutive cases of renal cell carcinoma diagnosed at our hospital. In 178 surgical treatment was done to achieve cure and in 6 patients it was palliative. No statistical differences in survival were found according to the surgical approach, or extensive vs hilar lymphadenectomy, or in the presence or absence of venous involvement. There were statistical differences in survival depending on the tumor stage and an inverse correlation between survival and tumor size. Sixty-nine cases received complementary treatments. Radiotherapy, alpha 2b interferon and vinblastine, resection of metastasis, or gestagen therapy failed to improve survival. No improvement in survival was achieved with palliative embolization, but it ameliorated local symptoms. The mean survival in patients with metastasis and without treatment was 5.5 months and there was no statistical difference in survival relative to the number of site of metastasis, or the number of affected viscera. The mean survival in patients that were not operated and had no metastasis was greater: 23.5 months. Surgery, regardless of the surgical approach or type of lymphadenectomy, is the only treatment that improves survival in renal cell carcinoma. Patients with metastasis receiving no treatment have a worse prognosis.